Literature DB >> 18389387

Cascade genetic testing for mismatch repair gene mutations.

R J Mitchell1, R K Ferguson, A Macdonald, M G Dunlop, H Campbell, M E Porteous.   

Abstract

Mismatch repair gene mutation carriers have a high risk of developing colorectal cancer, and can benefit from appropriate surveillance. A combined population based ascertainment cascade genetic testing approach provides a systematic and potentially effective strategy for identifying such carriers. We have developed a Markov Chain computer model system which simulates various factors influencing cascade genetic testing; including demographics, uptake, genetic epidemiology and family size. This was used to evaluate cascade genetic testing for mismatch repair gene mutations in theory and practice. Simulations focussed on the population of Scotland by way of illustration, and were based on a 20-year programme in which index cases were ascertained from colorectal cancer cases aged<55 years at onset. Results indicated that without practical barriers to cascade genetic testing, 545 (95% CI=522, 568) carriers could be identified; 42% of the population total. This comprised approximately 140 index cases, 302 asymptomatic relatives and 104 previously affected relatives. However, when realistic ascertainment and acceptance rates were used to inform simulations, only 257 (95% CI=246, 268) carriers, about 20% of the carrier population, were identifiable. Of these approximately 112 were index cases, 108 were asymptomatic relatives, and 37 were previously affected relatives. This contrast emphasises the importance of ascertainment and acceptance rates. Likewise the low number of index cases shows that case identification is a limiting factor. In the absence of robust data from epidemiological studies, these findings can inform decisions about the use of cascade genetic testing for mismatch repair gene mutations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18389387     DOI: 10.1007/s10689-008-9192-x

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  30 in total

1.  Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction.

Authors:  K Aktan-Collan; J P Mecklin; H Järvinen; M Nyström-Lahti; P Peltomäki; I Söderling; A Uutela; A de la Chapelle; H Kääriäinen
Journal:  Int J Cancer       Date:  2000-01-20       Impact factor: 7.396

2.  Is cascade testing a sensible method of population screening?

Authors:  J K Morris
Journal:  J Med Screen       Date:  2004       Impact factor: 2.136

3.  Estimates of true birth order for Scotland, 1945-1999.

Authors:  Jessica Chamberlain; Steve Smallwood
Journal:  Popul Trends       Date:  2004

4.  Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia.

Authors:  Dalya Marks; David Wonderling; Margaret Thorogood; Helen Lambert; Steve E Humphries; H Andrew W Neil
Journal:  BMJ       Date:  2002-06-01

5.  Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment.

Authors:  F Quehenberger; H F A Vasen; H C van Houwelingen
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

6.  Genetic instability occurs in the majority of young patients with colorectal cancer.

Authors:  B Liu; S M Farrington; G M Petersen; S R Hamilton; R Parsons; N Papadopoulos; T Fujiwara; J Jen; K W Kinzler; A H Wyllie; B Vogelstein; M G Dunlop
Journal:  Nat Med       Date:  1995-04       Impact factor: 53.440

7.  Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study.

Authors:  Mark A Jenkins; Shinichi Hayashi; Anne-Marie O'Shea; Lawrence J Burgart; Tom C Smyrk; David Shimizu; Paul M Waring; Andrew R Ruszkiewicz; Aaron F Pollett; Mark Redston; Melissa A Barker; John A Baron; Graham R Casey; James G Dowty; Graham G Giles; Paul Limburg; Polly Newcomb; Joanne P Young; Michael D Walsh; Stephen N Thibodeau; Noralane M Lindor; Loïc Lemarchand; Steven Gallinger; Robert W Haile; John D Potter; John L Hopper; Jeremy R Jass
Journal:  Gastroenterology       Date:  2007-04-25       Impact factor: 22.682

8.  Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis.

Authors:  H F Vasen; J T Wijnen; F H Menko; J H Kleibeuker; B G Taal; G Griffioen; F M Nagengast; E H Meijers-Heijboer; L Bertario; L Varesco; M L Bisgaard; J Mohr; R Fodde; P M Khan
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

9.  Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome.

Authors:  M G Dunlop
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

10.  Population carrier frequency of hMSH2 and hMLH1 mutations.

Authors:  M G Dunlop; S M Farrington; I Nicholl; L Aaltonen; G Petersen; M Porteous; A Carothers
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.